Vumerity Dosage

Blood Tests Prior to Initiation of VUMERITY

Obtain the following prior to treatment with VUMERITY:

• A complete blood cell count (CBC), including lymphocyte count.
• Serum aminotransferase, alkaline phosphatase, and total bilirubin levels.

Dosing Information

The starting dosage for VUMERITY is 231 mg twice a day orally. After 7 days, the dosage should be increased to the maintenance dosage of 462 mg (administered as two 231 mg capsules) twice a day orally. Temporary dosage reductions to 231 mg twice a day may be considered for individuals who do not tolerate the maintenance dosage. Within 4 weeks, the recommended dosage of 462 mg twice a day should be resumed. Discontinuation of VUMERITY should be considered for patients unable to tolerate return to the maintenance dosage. Administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to VUMERITY dosing may reduce the incidence or severity of flushing.

Administration Instructions

Swallow VUMERITY capsules whole and intact. Do not crush or chew, or sprinkle the capsule contents on food.

If taken with food, avoid a high-fat, high-calorie meal/snack; the meal/snack should contain no more than 700 calories and no more than 30 g fat.

Avoid co-administration of VUMERITY with alcohol.

Blood Tests to Assess Safety After Initiation of VUMERITY

Obtain a complete blood cell count (CBC), including lymphocyte count, 6 months after initiation of VUMERITY and then every 6 to 12 months thereafter, as clinically indicated.

Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels during treatment with VUMERITY, as clinically indicated.

Patients With Renal Impairment

No dosing adjustment is recommended in patients with mild renal impairment.

VUMERITY is not recommended in patients with moderate or severe renal impairment.